Opendata, web and dolomites

REPO-TRIAL SIGNED

An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 REPO-TRIAL project word cloud

Explore the words cloud of the REPO-TRIAL project. It provides you a very rough idea of what is the project "REPO-TRIAL" about.

discovered    experimentation    innovative    mechanistic    cerebro    benefit    medicine    phenotype    reduces    applicable    efficacy    clinical    patients    precision    generates    vagueness    describe    silico    competitiveness    symptom    our    systematic    biomolecular    novo    apparent    gov    trials    classes    size    enhances    disease    validation    scientifically    cardiovascular    pendant    org    diseases    panel    disturbance    virtual    equilibria    clinicaltrials    self    drug    putatively    animal    prcts    computer    generally    drugs    frame    stratified    translation    chosen    randomised    de    validate    innovate    risks    regulation    repurposing    unrealistic    diagnostics    reduce    phenotypes    reviews    platform    confirmatory    definitions    choose    identifies    exclusive    time    repositionings    mechanistically    trial    industrial    facilitated    preclinical    simulation    of    rapid    organ    meta    models    biomedical    cohort    reducing    biomarker    patient   

Project "REPO-TRIAL" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://repo-trial.eu/
 Total cost 5˙536˙775 €
 EC max contribution 5˙536˙772 € (100%)
 Programme 1. H2020-EU.3.1.5. (Methods and data)
 Code Call H2020-SC1-2017-CNECT-2
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2023-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 1˙270˙089.00
2    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 844˙728.00
3    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 742˙045.00
4    UNIVERSITAETSKLINIKUM ESSEN DE (ESSEN) participant 597˙565.00
5    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 550˙722.00
6    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 550˙722.00
7    Concentris Research Management GmbH DE (Fürstenfeldbruck) participant 355˙026.00
8    SOMALOGIC LIMITED UK (CHOBHAM) participant 342˙964.00
9    BIOCRATES LIFE SCIENCES AG AT (INNSBRUCK) participant 157˙789.00
10    MUCKE HERMANN AT (WIEN) participant 125˙122.00
11    SYDDANSK UNIVERSITET DK (ODENSE M) participant 0.00

Map

 Project objective

Our programme will develop an innovative in-silico based approach to improve the efficacy and precision of drug repurposing trials. We have chosen drug repurposing as it has the shortest time for clinical validation and translation. Validation of all putatively de novo discovered drug repositionings within the time-frame of this programme would be unrealistic. To improve efficacy and precision, and to adopt our computer simulation parameters and models, we choose a systems medicine based in-silico approach that identifies mechanistically related disease phenotypes and, as a result, a virtual patient cohort. We then validate this in-silico drug repurposing via high precision clinical trials in patients with cerebro-cardiovascular phenotypes stratified using an exclusive mechanistic biomarker panel. We thus innovate two biomedical product classes, drugs and diagnostics. With this we will establish generally applicable in silico trials for other mechanistically related or defined disease phenotypes, for which size, duration, and risks will be reduced and precision increased. This generates rapid patient benefit, reduces drug development costs as well as risks, and enhances industrial competitiveness. Scientifically, we will contribute to reducing the uncertainty and vagueness of many of our current disease definitions that describe a symptom or apparent phenotype in an organ rather than defining diseases mechanistically as disturbance of self-regulation equilibria of biomolecular processes. Finally, we will reduce animal experimentation and animal numbers in general by applying a preclinical randomised confirmatory trial (pRCTs) concept and preclinical systematic reviews and meta-analyses facilitated by our open access pre-clinicaltrials.org platform, a pendant to clinicaltrials.gov.

 Deliverables

List of deliverables.
Project brochure and professional templates Websites, patent fillings, videos etc. 2019-11-06 13:06:26
Software for detection of pathway co-enrichment for extracting of patient(group)-specific pathways also enriched in target sites of effective drugs Other 2019-11-06 13:06:20
Communication and dissemination plan Websites, patent fillings, videos etc. 2019-11-06 13:06:11
Diseasome 2.0 network Other 2019-11-06 13:06:12

Take a look to the deliverables list in detail:  detailed list of REPO-TRIAL deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Mahmoud H. Elbatreek, Mayra P. Pachado, Antonio Cuadrado, Karin Jandeleit-Dahm, Harald H.H.W. Schmidt
Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage
published pages: 312-327, ISSN: 1043-2760, DOI: 10.1016/j.tem.2019.02.006
Trends in Endocrinology & Metabolism 30/5 2019-09-26
2019 Ana I. Casas, Pamela W.M. Kleikers, Eva Geuss, Friederike Langhauser, Thure Adler, Dirk H. Busch, Valerie Gailus-Durner, Martin Hrabê de Angelis, Javier Egea, Manuela G. Lopez, Christoph Kleinschnitz, Harald H.H.W. Schmidt
Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke
published pages: 1772-1778, ISSN: 0021-9738, DOI: 10.1172/jci124283
Journal of Clinical Investigation 129/4 2019-09-26
2019 Ana I. Casas, Ahmed A. Hassan, Simon J. Larsen, Vanessa Gomez-Rangel, Mahmoud Elbatreek, Pamela W. M. Kleikers, Emre Guney, Javier Egea, Manuela G. López, Jan Baumbach, Harald H. H. W. Schmidt
From single drug targets to synergistic network pharmacology in ischemic stroke
published pages: 7129-7136, ISSN: 0027-8424, DOI: 10.1073/pnas.1820799116
Proceedings of the National Academy of Sciences 116/14 2019-09-26
2018 Joaquim Aguirre-Plans, Janet Piñero, Jörg Menche, Ferran Sanz, Laura Furlong, Harald Schmidt, Baldo Oliva, Emre Guney
Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology
published pages: 61, ISSN: 1424-8247, DOI: 10.3390/ph11030061
Pharmaceuticals 11/3 2019-09-26
2018 Simon J Larsen, Richard Röttger, Harald H H W Schmidt, Jan Baumbach
E. coli gene regulatory networks are inconsistent with gene expression data
published pages: 85-92, ISSN: 0305-1048, DOI: 10.1093/nar/gky1176
Nucleic Acids Research 47/1 2019-09-26

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REPO-TRIAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REPO-TRIAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

Instand-NGS4P (2020)

Integrated and standardized NGS workflows for Personalised therapy

Read More  

EUCAN-Connect (2019)

A federated FAIR platform enabling large-scale analysis of high-value cohort data connecting Europe and Canada in personalized health

Read More  

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

Read More